Hologic (NASDAQ: [[ticker:HOLX]]), a Bedford, MA-based developer of diagnostic and medical imaging devices, announced today that it has bought Beijing-based TCT International for $135 million in cash, with $35 million of that deferred for one year, plus a two-year contingent earn out. TCT is a distributor of medical products and instruments in China, including Hologic’s ThinPrep Pap Test. “We firmly believe by controlling a distribution channel as extensive as TCT’s, we can better leverage our entire product portfolio to drive growth across multiple market segments,” said Hologic president and CEO Rob Cascella in the announcement of the deal.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
